#PeptideTherapy #BPC157 #MetabolicHealth #VitalityOptimization #FunctionalMedicine #CDRXPharmacy #CompoundingPartners To view or add a comment, sign in The FDA has granted Priority Review to asundexian, an investigational oral factor XIa inhibitor manufactured by Bayer, for secondary stroke prevention after noncardioembolic ischemic stroke or transient ischemic attack
Dc ng hc l nhng tc ng ca c th i vi thuc trong sut qu trnh thuc i vo, trong v i ra khi c th- bao gm cc qu trnh hp th, sinh kh dng, phn b, chuyn ha, v thi tr
Ingredients Active Ingredient: Reduced Glutathione 1200mg Other Ingredients: Stabilizing agents as formulated by the manufacturer Product Specifications Storage Instructions Store in a cool, dry place away from direct sunlight
However, pharmaceutical BMP products expensive ($5,000-$10,000 per treatment) and carry side effects (ectopic bone formation, inflammation)